United Therapeutics to Present New Clinical Data on Pulmonary Hypertension and Inhaled Treprostinil at CHEST 2025 Annual Meeting
United Therapeutics Corporation will present new clinical data on pulmonary hypertension and inhaled treprostinil at the CHEST 2025 Annual Meeting in Chicago from October 19-22, 2025. The presentations will include interim analysis results from the PHINDER Study and data on inhaled treprostinil's impact on hospitalizations in PH-ILD patients. The company will also sponsor events, including a symposium on PH-ILD management and the Women in Chest Medicine Annual Luncheon.
United Therapeutics Corporation announced that it will feature new clinical data at the upcoming CHEST 2025 Annual Meeting, scheduled for October 19-22, 2025, in Chicago. The company will present two oral presentations, including interim analysis results from the PHINDER Study on echocardiographic features of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), and data on the impact of inhaled treprostinil initiation timing on hospitalizations in PH-ILD patients. These results will be presented at the meeting and have not yet been disclosed publicly. United Therapeutics will also sponsor several events at the conference, such as a symposium on best practices in PH-ILD detection and management, and the Women in Chest Medicine Annual Luncheon. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251013658816) on October 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
